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A B S T R A C T
Sudden unexpected death in epilepsy (SUDEP) primarily affects young adults and is the leading cause of
death related directly to seizures. High frequency of generalized tonic-clonic seizures is the most
important risk factor, and effective seizure protection is probably the most important measure to prevent
these tragic deaths. For several years a potential role of antiepileptic drugs (AEDs) has been discussed, but
at present there is wide agreement that choice of AED therapy does not inﬂuence the risk. However,
although it is well known that the efﬁcacy and safety proﬁles of AEDs may differ signiﬁcantly when used
in the treatment of genetic epilepsy compared to symptomatic or cryptogenic epilepsy, this has generally
been overlooked in epidemiologic studies of possible relationships between AEDs and SUDEP.
Consequently important information about drug safety may have been lost. This review challenges
the current view that no AED can increase the risk of SUDEP.
ã 2016 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Sudden unexpected death in epilepsy (SUDEP) primarily affects
young adults. Among neurological conditions causing loss of
potential years of life, SUDEP ranges second only to stroke [1].
SUDEP is the leading cause of death related directly to seizures
[2,3].
A potential role of antiepileptic drugs (AEDs) in SUDEP has been
discussed for several years, and, at present, the leading interpre-
tation of the existing literature is that there is no scientiﬁc
evidence that any AED can increase the risk [4–8]. The aim of this
review is to identify and discuss the strong scientiﬁc reasons for
giving greater nuance to this widespread perception.
2. Search strategy and selection criteria
We used PubMed to search for references, and references from
relevant articles, using the search terms “epilepsy”, “epileptic”,
“antiepileptic”, “drugs”, “seizures”, “risk factors”, “sudden”,
“death”, “genetic”, “mechanisms”, “cardiac”, “arrhythmia” and
“psychiatric”. Only articles in English and published between
1970 and June 2016 were included.* Corresponding author at: Neuroscience Research Group and Department of
Neurology, Stavanger University Hospital, P.O. Box 8100, Stavanger, NO 4068,
Norway.
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creativecommons.org/licenses/by-nc-nd/4.0/).References were selected from the identiﬁed articles according
to their relevance for this review. Using the combination of search
terms “SUDEP and epilepsy and risk factors” 233 articles were
identiﬁed. Among these all studies using living patients with
epilepsy as controls examining a possible connection between
individual AEDs and SUDEP were selected and included in the
review.
3. Pathophysiological mechanisms and risk factors
SUDEP is deﬁned as “sudden, unexpected, witnessed or unwit-
nessed, nontraumatic and nondrowning death, occurring in benign
circumstances, in an individual with epilepsy, with or without
evidence for a seizure and excluding documented status epilepticus
(seizure duration  30 min or seizures without recovery in between),
in which postmortem examination does not reveal a cause of death”
[9]. The majority of documented observed cases of SUDEP has
occurred in association with a generalized tonic-clonic seizure
(GTCS) [10–12], although recent evidence suggests that it may also
occur without an associated seizure [13]. The cause in individual
cases is usually unknown. Nevertheless, there is considerable
evidence that respiratory or cardiac mechanisms, separately or in
combination, are often involved [14]. Based on documented cases
of SUDEP, in which seizure activity was abruptly followed by
ﬂattening of the EEG, electrocerebral shutdown has also been
proposed as a separate mechanism [15]. Interestingly, the
occurrence of ictal hypoxia signiﬁcantly increases the risk of
concomitant cardiac dysfunction [16].Association. This is an open access article under the CC BY-NC-ND license (http://
D. Aurlien et al. / Seizure 43 (2016) 56–60 57Interictally, at the group level, the occurrence of cardiac
arrhythmias in individuals with epilepsy does not differ signiﬁ-
cantly from that in the general population [17,18]. However,
arrhythmias occur in a signiﬁcant proportion of seizures, ranging
from benign sinustachycardia or bradycardia [19–23] to potentially
serious or fatal arrhythmias, including marked sinus arrhythmia,
asystole, bundle-branch block, ST-segment elevation or depres-
sion, T-wave inversion, or prolongation or shortening of the QT
interval [19–21,24,25].
Several studies have documented an association between
SUDEP and high seizure frequency [12,26–28] and a history of
frequent GTCSs is probably the single most important risk factor
for SUDEP [29–32]. In addition, among several studies focusing on
different aspects of predisposition, long duration of epilepsy and
use of polytherapy have been the most consistently identiﬁed risk
factors [33].
4. Inappropriate choice of AED therapy may increase the risk of
SUDEP
The importance of effective AED treatment in the prevention of
SUDEP has been well documented. Whereas untreated patients
have been found to be at the highest risk [12], individuals with
uncontrolled seizures that have received add-on therapy in
effective dosages have reduced their risk more than seven times
compared with placebo [34]. Whether or not single speciﬁc AEDs
can increase the risk of SUDEP has been much debated in recent
years. There appears to be broad agreement that if a signiﬁcant
difference is detected between the proportion of SUDEP victims on
a certain AED and the proportion on the same drug among controls,
then when evaluating whether there is a causal relationship the
numbers should be corrected for the frequency of GTCSs [4,5,35].
Importantly, however, it has not been acknowledged that in
correcting for seizure frequency, the inﬂuence of AED efﬁcacy,
which has been demonstrated to be crucial in the prevention of
SUDEP, is simultaneously eliminated [34]. A relationship could be
regarded as causal, in the sense that an increased occurrence of
SUDEP may be caused by an unfavorable choice of AED that
provides inferior protection against GTCSs.
5. Channelopathies and AEDs
Channelopathies are diseases caused by mutations in genes
coding for ion channels. They are often genotypically and
phenotypically heterogeneous, i.e., a certain genetic disorder
may be caused by different mutations, and a given mutation may
give rise to different phenotypes in the same family [36,37]. The
genetic epilepsies have been associated with mutations in genes
coding for sodium-, potassium-, calcium- and chloride channels, as
well as the nicotinergic acetylcholine receptor and the gamma-
aminobutyric acid (GABA) receptor. Among these, sodium channel
mutations are the most common [38,39].
Although non channel mechanisms may be involved, blockade of
ion channels is the most important mechanism of action for the
majority of AEDs [40]. Many of these are sodium channel blockers
and, when used to treat genetic epilepsy, may not only provide
inferiorefﬁcacy, butevencauseseizureaggravation. Forexample, the
sodium channel blockers phenytoin (PHT), carbamazepine (CBZ),
and lamotrigine (LTG) [41] can cause paradoxical seizure aggrava-
tion, particularly in juvenile myoclonic epilepsy of myoclonic jerks
[42], and LTG can aggravate severe myoclonic epilepsy of infancy
(SMEI; Dravet syndrome) [43], which is caused by a mutation in the
neuronal sodium channel gene SCN1A [44]. Nevertheless, inves-
tigations of possible associations between AEDs and SUDEP have
been performed only at the group level, without examining the
genetic epilepsies separately [4,12,26,27,45–47].Congenital long QT syndrome (cLQTS) is caused by mutations in
genes coding for cardiac ion channels, mainly potassium channels
and, in a smaller proportion, sodium channels [48,49]. It is
associated with prolongation of the QT interval in the ECG and a
propensity to syncope, torsade de pointes arrhythmia, and
ventricular ﬁbrillation [48,50]. Several drugs, including antipsy-
chotics, antihistamines, and antibiotics, can inhibit the cardiac
potassium ion current IKr, and several IKr blocking drugs have been
excluded or withdrawn from the market because of an unaccept-
ably high occurrence of QT interval prolongation, syncope, and
sudden death [51,52]. Importantly, individuals with the cLQTS are
particularly vulnerable and should generally avoid IKr-blocking
drugs [53].
In recent years, increasing evidence has emerged indicating
that cardiac and neuronal channelopathies are overlapping. Many
of the cardiac ion channel genes causing cLQTS are also expressed
in the brain [54]. Animal studies [55,56], along with clinical studies
[57,58] and casuistic reports [59–62], suggest that cardiac
channelopathies may also be associated with epilepsy. Evidence
for the converse, however, that neuronal channelopathies can
predispose a patient to cardiac arrhythmia, is sparse. Nevertheless,
in casuistic reports of SUDEP in patients with generalized epilepsy
with febrile seizures plus (GEFS+) and Dravet syndrome, there has
been discussion regarding whether a genetic disposition to fatal
cardiac arrhythmia could occur, as the gene product of SCN1A,
NaV1.1, is expressed in the heart of mammals [63,64].
Although non channel or non cardiac mechanisms may possibly
be involved explaining an association between an AED and SUDEP
a key question is whether drugs with the potential to prolong the
QT interval can increase the risk of a fatal seizure-related cardiac
arrhythmia in genetically predisposed individuals. This possibility
was recently addressed in an Australian study of 61 SUDEP victims,
in which genetic analysis revealed mutations indicating a
predisposition to cardiac arrhythmia in 13 of the deceased; 7%
(4/61) had mutations in LQTS genes and 15% (9/61) had mutations
in other cardiac arrhythmia genes [65].
6. Individual AEDs and SUDEP
Several AEDs are associated with abnormalities in the cardiac
conduction system and rhythmicity, mainly in predisposed
individuals [66–68]. CBZ and intravenous PHT can give rise to
sinus bradycardia, sinus arrest, and atrioventricular block [69–71],
whereas lacosamide has shown a tendency to induce atrioventric-
ular block [72]. In addition, the QT interval can be increased by
retigabine (Trobalt European Public Assessment Report, EPAR.
Committee for Medicinal Products for Human Use (CHMP): www.
ema.europa.eu/ema/) and CBZ and primidone can shorten it
[67,73]. PHT, phenobarbital (PB), and LTG have been shown to
inhibit the IKr [74,75] and a possible role in SUDEP has been
suggested. However, among epidemiological studies focusing on a
possible relationship between AEDs and SUDEP, only CBZ and LTG
have been suggested as being implicated (Table 1) [12,46,47,76,77].
7. CBZ and SUDEP
CBZ was ﬁrst discussed as a possible risk factor for SUDEP in a
study from the Cardiff Epilepsy Unit in 1998, in which 85% of
SUDEP victims that were on AED therapy at the time of death were
treated with CBZ, compared with only 38% of controls (p < 0.01)
[47]. Importantly, in this cohort as many as 10 of the 14 SUDEP
victims had idiopathic generalized epilepsy (IGE) [78], and 11/
14 were on CBZ which, when used in the treatment of IGE, may
cause seizure aggravation (Table 1) [79]. Three years later, a
Swedish case-control study identiﬁed high levels of CBZ as a risk
factor for SUDEP [46], although it was emphasized that there was
Table 1
Studies examining possible associations between individual AEDs and SUDEP.
Type of study Cases (n)/
controls (n)
AED(s)
evaluated
Result Interpretation by authors
Timmings, 1998 [47] Review of SUDEP cases,
comparison with
average CBZ usage in
the cohort
14/1851 CBZ 11/13 (85%) of SUDEP cases were
on CBZ, vs. 38% on CBZ in the
cohort (p < 0.01)
CBZ possibly involved through pro-
arrhythmogenic effect
Nilsson et al., 1999 [26] Nested case-control 57/171 PHT, CBZ,
VPA
No AED associated with
increased risk
Large cohort and differences in SUDEP criteria
and selection of cases and controls may explain
the lack of association with CBZ
Nilsson et al., 2001
[46]
Nested case-control 57/171 PHT, CBZ,
VPA
High CBZ levels associated with
increased risk
Association may not be caused by CBZ per se, can
be a surrogate of poor seizure control
Walczak et al., 2001
[27]
Nested case-control 20/80 Not speciﬁed Serum concentrations of PHT and
CBZ similar as in controls
No AED associated with SUDEP
Langan et al., 2005 [12] Nested case-control 154 cases.
4 controls for
each case, exact
number not
speciﬁed
CBZ Signiﬁcantly increased risk with
CBZ
Confounding factors may be present. Causality
should not be assumed
Hitiris et al., 2007 [45] Nested case-control 62/124 CBZ No association with CBZ Theories why studies differ concerning CBZ and
SUDEP not speciﬁed
Hesdorffer et al., 2011
[76]
Combined analysis of
four nested case-
control studies
289/958 PHT, CBZ,
VPA, LTG
In univariate analysis
signiﬁcantly increased risk with
LTG in IGE
Increased risk with LTG may be caused by inferior
efﬁcacy in IGE or arrhythmogenic effect. Further
independent studies needed to exclude or
conﬁrm an association
Aurlien et al., 2012 [77] Nested case-control 19/63 CBZ, VPA,
LTG
Signiﬁcantly increased risk in
females on LTG
Causal association possible in females with
genetic epilepsy treated with LTG
Hesdorffer et al., 2012
[4]
Combined analysis of
three nested case-
control studies
216/831 PHT, CBZ,
VPA, LTG
No AED associated with
increased risk after correction for
the frequency of GTCSs at the
group level
The study provided a “consistent message that
number of GTCS increases SUDEP risk and not AEDs”
Tomson et al., 2012
[35]
Analysis of SUDEP
incidence in
42 GlaxoSmithKline
randomized-
controlled trials
>4631/>3131
(Exact numbers
not speciﬁed)
LTG No signiﬁcant increase in SUDEP
rates with LTG. Although there
was no SUDEP among
individuals with only
generalized seizures the
proportion was too low to permit
conclusions for this subgroup of
patients
Wide conﬁdence intervals, clinically signiﬁcant
inﬂuence on SUDEP rates by LTG cannot be
excluded
AED, antiepileptic drug; CBZ, carbamazepine; GTCSs, generalized tonic-clonic seizures; LTG, lamotrigine; PHT, phenytoin; SUDEP, sudden unexpected death in epilepsy; VPA,
valproate.
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present. However, in contrast, two later reports found no
association between CBZ and SUDEP [27,45]. Furthermore, a large
study that included 216 SUDEP cases concluded after correcting for
the frequency of GTCSs, that neither the use of CBZ nor any other
AED could increase the risk of SUDEP [4]. No increase in SUDEP risk
associated with CBZ in monotherapy was detected in the crude
analysis (odds ratio 0.7; 95% CI 0.3–1.4), as opposed to CBZ in
polytherapy (odds ratio 2.8; 95% CI 1.5–5.3) [4]. As there was no
increase in risk with monotherapy in the crude analysis, correction
for seizure frequency, which principally eliminates the inﬂuence of
AED efﬁcacy, cannot explain the ﬁnding of a lack of association
between CBZ in monotherapy and SUDEP. Nevertheless, a sub-
group analysis of individuals with IGE was not performed, and an
increased risk with CBZ in IGE cannot be completely excluded
based on this study.
8. LTG and SUDEP
Following a clinical observation of four consecutive cases of
SUDEP in females with idiopathic epilepsy that had all been treated
with LTG in monotherapy, the question was raised as to whether
there could be a connection between treatment with LTG in
idiopathic epilepsy and SUDEP [80]. One possible explanation that
was discussed was that inhibition of the cardiac IKr current by LTG
[74] could cause fatal arrhythmia in genetically predisposed
individuals. Additionally, the preponderance of females could
reﬂect up to threefold higher risk of drug-induced torsade de
pointes arrhythmia in females [81,82]. In line with this, four yearslater the International League Against Epilepsy (ILAE) Commission
on Epidemiology; Subcommission on Mortality, concluded from
their combined analysis of 289 SUDEP cases from four different
case-control studies that, using univariate analysis, treatment with
LTG was associated with a signiﬁcantly increased risk of SUDEP
[76]. Importantly, however, when “IGE” and “not IGE” were
analyzed separately, the elevated risk was only present in IGE.
Conforming with this, a Norwegian study found that the
proportion of female SUDEP victims on LTG was signiﬁcantly
higher than the proportion of living female controls with epilepsy
on LTG, and that there was a ﬁvefold higher incidence of SUDEP in
females on LTG than in females with epilepsy that were not on LTG
[77]. Again, there were no indications of an increased risk in
symptomatic epilepsy; the increased risk associated with LTG
treatment was apparently only present in idiopathic epilepsy. At
the same time as the Norwegian report was published, a new
report concluded that, after correcting for the frequency of GTCSs,
neither the use of LTG nor any other AED causes an increased risk of
SUDEP, as opposed to a high frequency of GTCSs [4]. As the
correction for seizure frequency was performed only at the group
level, the patient material with an increased risk (IGE) of SUDEP
was diluted by the larger subgroup without an increased risk (not
IGE). Consequently, the conclusion that there is no causal
relationship between LTG treatment and SUDEP that is based on
this analysis, is, in our opinion, not valid for the subgroup with IGE.
Interestingly, however, and supporting the results of the
Norwegian study [77], the odds ratio for SUDEP in patients on
LTG in monotherapy compared with controls was 6.6 for females
(95% CI 0.3–174.9) and 0.4 in males (95% CI 0.1–2.8) [4]. Again, the
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possible that the lack of statistical signiﬁcance could be due to
dilution of the material.
The importance of AED efﬁcacy in protection against SUDEP
was not acknowledged in the ILAE study that claimed an absence of
causal relationship between LTG use and SUDEP [4]. Clinical
studies have indicated that LTG in IGE provides inferior seizure
protection compared with valproate [83,84], which has been
recommended as a ﬁrst-line drug in IGE because of its efﬁcacy [85].
As the most important risk factor for SUDEP is probably a high
frequency of GTCSs, use of LTG in IGE with GTCSs could be expected
to result in more SUDEP. In summary, the increased occurrence of
SUDEP in patients with IGE on LTG could be partly due to a cardiac
side effect in genetically predisposed individuals, and partly due to
insufﬁcient efﬁcacy; both factors are of importance and may both
contribute to SUDEP.
9. AEDs in psychiatry and neuropathic pain
AEDs are also widely used in the treatment of neuropathic pain
and psychiatric disorders. To our knowledge, there is no evidence
of an increased occurrence of sudden death associated with
neuropathic pain syndromes, but among individuals with psychi-
atric diseases the incidence of sudden death is signiﬁcantly
elevated [86]. The reasons for this are probably multifactorial,
including an increased occurrence of cardiovascular disease in this
population [87]. However, several antipsychotics and antidepres-
sants possess the ability to inhibit the IKr and have been associated
with increased risk of QT interval prolongation, torsade de pointes
arrhythmia, and sudden death [88]. Whether AEDs that can inhibit
the IKr contribute to the greater occurrence of arrhythmias and
sudden death in patients with psychiatric disorders have not been
explored scientiﬁcally as far as we are aware. However, combining
drugs with IKr blocking properties may be hazardous [74,88]; thus
treatment with a combination of an IKr-blocking AED and a
psychotropic drug, particularly in patients with a predisposition to
cardiac arrhythmia, may put the patients at an unacceptably
elevated risk of sudden death.
10. Conclusions
A high frequency of GTCSs is probably the single most
important risk factor for SUDEP, and therefore effective AED
therapy remains a cornerstone in its prevention. Thus, optimal
choice of treatment, according to epilepsy syndrome and seizure
type, is key for reducing the risk of SUDEP.
Because the efﬁcacy and safety proﬁles of AEDs may differ,
studies on possible associations between AED treatment and
SUDEP should be performed separately for genetic epilepsy and
symptomatic or cryptogenic epilepsy.
In patients with a predisposition to cardiac arrhythmia, caution
should be exercised when considering the introduction of AEDs
with the potential to interfere with cardiac rhythmicity or
conduction system. Caution is particularly recommended in
prescribing LTG for treatment of females with IGE and GTCSs.
Importantly, however, this should not discourage the use of LTG in
symptomatic or cryptogenic epilepsy in which there is no scientiﬁc
evidence suggesting an increased risk.
Advances in detecting mutations that may predispose patients
to serious cardiac arrhythmias will hopefully enable clinicians to
improve safety in the treatment of people with epilepsy.
Conﬂict of interest statement
The authors have no conﬂict of interest.References
[1] Thurman DJ, Hesdorffer DC, French JA. Sudden unexpected death in epilepsy:
assessing the public health burden. Epilepsia 2014;55:1479–85.
[2] Nashef L, Fish DR, Sander JW, Shorvon SD. Incidence of sudden unexpected
death in an adult outpatient cohort with epilepsy at a tertiary referral centre. J
Neurol Neurosurg Psychiatry 1995;58:462–4.
[3] Sillanpaa M, Shinnar S. Long-term mortality in childhood-onset epilepsy. N
Engl J Med 2010;363:2522–9.
[4] Hesdorffer DC, Tomson T, Benn E, Sander JW, Nilsson L, Langan Y, et al. Do
antiepileptic drugs or generalized tonic-clonic seizure frequency increase
SUDEP risk? A combined analysis. Epilepsia 2012;53:249–52.
[5] Pack AM. SUDEP: what are the risk factors? Do seizures or antiepileptic drugs
contribute to an increased risk. Epilepsy Curr 2012;12:131–2.
[6] Malik GA, Smith PE. Increasing awareness of sudden unexpected death in
epilepsy. Expert Rev Neurother 2013;13:1371–82.
[7] Verma A, Kumar A. Sudden unexpected death in epilepsy: some approaches to
prevent it. J Neuropsychiatry Clin Neurosci 2015;27:e28–31.
[8] Hesdorffer DC, Tomson T. Sudden unexpected death in epilepsy: potential role
of antiepileptic drugs. CNS Drugs 2013;27:113–9.
[9] Nashef L, So EL, Ryvlin P, Tomson T. Unifying the deﬁnitions of sudden
unexpected death in epilepsy. Epilepsia 2012;53:227–33.
[10] Terrence Jr. CF, Wisotzkey HM, Perper JA. Unexpected, unexplained death in
epileptic patients. Neurology 1975;25:594–8.
[11] Langan Y, Nashef L, Sander JW. Sudden unexpected death in epilepsy: a series
of witnessed deaths. J Neurol Neurosurg Psychiatry 2000;68:211–3.
[12] Langan Y, Nashef L, Sander JW. Case-control study of SUDEP. Neurology
2005;64:1131–3.
[13] Lhatoo SD, Nei M, Raghavan M, Sperling M, Zonjy B, Lacuey N, et al. Nonseizure
SUDEP: sudden unexpected death in epilepsy without preceding epileptic
seizures. Epilepsia 2016;57:1161–8.
[14] Massey CA, Sowers LP, Dlouhy BJ, Richerson GB. Mechanisms of sudden
unexpected death in epilepsy: the pathway to prevention. Nat Rev Neurol
2014;10:271–82.
[15] McLean BN, Wimalaratna S. Sudden death in epilepsy recorded in ambulatory
EEG. J Neurol Neurosurg Psychiatry 2007;78:1395–7.
[16] Seyal M, Pascual F, Lee CYM, Li CS, Bateman LM. Seizure-related cardiac
repolarization abnormalities are associated with ictal hypoxemia. Epilepsia
2011;52:2105–11.
[17] Blumhardt LD, Smith PE, Owen L. Electrocardiographic accompaniments of
temporal lobe epileptic seizures. Lancet 1986;1:1051–6.
[18] Massetani R, Strata G, Galli R, Gori S, Gneri C, Limbruno U, et al. Alteration of
cardiac function in patients with temporal lobe epilepsy: different roles of
EEG–ECG monitoring and spectral analysis of RR variability. Epilepsia
1997;38:363–9.
[19] Nei M, Ho RT, Sperling MR. EKG abnormalities during partial seizures in
refractory epilepsy. Epilepsia 2000;41:542–8.
[20] Nei M, Sperling MR, Mintzer S, Ho RT. Long-term cardiac rhythm and
repolarization abnormalities in refractory focal and generalized epilepsy.
Epilepsia 2012;53:e137–40.
[21] Opherk C, Coromilas J, Hirsch LJ. Heart rate and EKG changes in 102 seizures:
analysis of inﬂuencing factors. Epilepsy Res 2002;52:117–27.
[22] Rugg-Gunn FJ, Simister RJ, Squirrell M, Holdright DR, Duncan JS. Cardiac
arrhythmias in focal epilepsy: a prospective long-term study. Lancet
2004;364:2212–9.
[23] Moseley BD, Wirrell EC, Nickels K, Johnson JN, Ackerman MJ, Britton J.
Electrocardiographic and oximetric changes during partial complex and
generalized seizures. Epilepsy Res 2011;95:237–45.
[24] Surges R, Scott CA, Walker MC, Enhanced QT. Shortening and persistent
tachycardia after generalized seizures. Neurology 2010;74:421–6.
[25] Brotherstone R, Blackhall B, McLellan A. Lengthening of corrected QT during
epileptic seizures. Epilepsia 2010;51:221–32.
[26] Nilsson L, Farahmand BY, Persson PG, Thiblin I, Tomson T. Risk factors for
sudden unexpected death in epilepsy: a case-control study. Lancet
1999;353:888–93.
[27] Walczak TS, Leppik IE, D'Amelio M, Rarick J, So E, Ahman P, et al. Incidence and
risk factors in sudden unexpected death in epilepsy: a prospective cohort
study. Neurology 2001;56:519–25.
[28] Surges R, Adjei P, Kallis C, Erhuero J, Scott CA, Bell GS, et al. Pathologic cardiac
repolarization in pharmacoresistant epilepsy and its potential role in sudden
unexpected death in epilepsy: a case-control study. Epilepsia 2010;51:233–42.
[29] Tomson T, Nashef L, Ryvlin P. Sudden unexpected death in epilepsy: current
knowledge and future directions. Lancet Neurol 2008;7:1021–31.
[30] Duncan S, Brodie MJ. Sudden unexpected death in epilepsy. Epilepsy Behav
2011;21:344–51.
[31] Shorvon S, Tomson T. Sudden unexpected death in epilepsy. Lancet
2011;378:2028–38.
[32] Surges R, Sander JW. Sudden unexpected death in epilepsy: mechanisms,
prevalence, and prevention. Curr Opin Neurol 2012;25:201–7.
[33] Surges R, Thijs RD, Tan HL, Sander JW. Sudden unexpected death in epilepsy:
risk factors and potential pathomechanisms. Nat Rev Neurol 2009;5:492–504.
[34] Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in
patients given adjunctive antiepileptic treatment for refractory seizures: a
meta-analysis of placebo-controlled randomised trials. Lancet Neurol
2011;10:961–8.
60 D. Aurlien et al. / Seizure 43 (2016) 56–60[35] Tomson T, Hirsch LJ, Friedman D, Bester N, Hammer A, Irizarry M, et al. Sudden
unexpected death in epilepsy in lamotrigine randomized-controlled trials.
Epilepsia 2013;54:135–40.
[36] Kullmann DM. Neurological channelopathies. Annu Rev Neurosci
2010;33:151–72.
[37] Hirose S. A new paradigm of channelopathy in epilepsy syndromes:
intracellular trafﬁcking abnormality of channel molecules. Epilepsy Res
2006;70(Suppl. 1):S206–17.
[38] Heron SE, Scheffer IE, Berkovic SF, Dibbens LM, Mulley JC. Channelopathies in
idiopathic epilepsy. Neurotherapeutics 2007;4:295–304.
[39] Oliva M, Berkovic SF, Petrou S. Sodium channels and the neurobiology of
epilepsy. Epilepsia 2012;53:1849–59.
[40] Perucca E. The pharmacology of new antiepileptic drugs: does a novel
mechanism of action really matter? CNS Drugs 2011;25:907–12.
[41] Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia
1995;36(Suppl. 2):S2–S12.
[42] Crespel A, Genton P, Berramdane M, Coubes P, Monicard C, Baldy-Moulinier M,
et al. Lamotrigine associated with exacerbation or de novo myoclonus in
idiopathic generalized epilepsies. Neurology 2005;65:762–4.
[43] Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine
and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508–
12.
[44] Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De
novo mutations in the sodium-channel gene SCN1A cause severe myoclonic
epilepsy of infancy. Am J Hum Genet 2001;68:1327–32.
[45] Hitiris N, Suratman S, Kelly K, Stephen LJ, Sills GJ, Brodie MJ. Sudden
unexpected death in epilepsy: a search for risk factors. Epilepsy Behav
2007;10:138–41.
[46] Nilsson L, Bergman U, Diwan V, Farahmand BY, Persson PG, Tomson T.
Antiepileptic drug therapy and its management in sudden unexpected death
in epilepsy: a case-control study. Epilepsia 2001;42:667–73.
[47] Timmings PL. Sudden unexpected death in epilepsy: is carbamazepine
implicated? Seizure 1998;7:289–91.
[48] Hedley PL, Jorgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink
PA, et al. The genetic basis of long QT and short QT syndromes: a mutation
update. Hum Mutat 2009;30:1486–511.
[49] Refsgaard L, Holst AG, Sadjadieh G, Haunso S, Nielsen JB, Olesen MS. High
prevalence of genetic variants previously associated with LQT syndrome in
new exome data. Eur J Hum Genet 2012;20:905–8.
[50] Da Costa A, Chalvidan T, Belounas A, Messier M, Viallet M, Mansour H, et al.
Predictive factors of ventricular ﬁbrillation triggered by pause-dependent
torsades de pointes associated with acquired long QT interval: role of QT
dispersion and left ventricular function. J Cardiovasc Electrophysiol
2000;11:990–7.
[51] Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al.
Relationships between preclinical cardiac electrophysiology, clinical QT interval
prolongation and torsade de pointes for a broad range of drugs: evidence for a
provisional safety margin in drug development. Cardiovasc Res 2003;58:32–45.
[52] Witchel HJ, Hancox JC. Familial and acquired long qt syndrome and the cardiac
rapid delayed rectiﬁer potassium current. Clin Exp Pharmacol Physiol
2000;27:753–66.
[53] Schwartz PJ. The congenital long QT syndromes from genotype to phenotype:
clinical implications. J Intern Med 2006;259:39–47.
[54] Nashef L, Hindocha N, Makoff A. Risk factors in sudden death in epilepsy
(SUDEP): the quest for mechanisms. Epilepsia 2007;48:859–71.
[55] Goldman AM, Glasscock E, Yoo J, Chen TT, Klassen TL, Noebels JL. Arrhythmia in
heart and brain: KCNQ1 mutations link epilepsy and sudden unexplained
death. Sci Transl Med 2009;1:2ra6.
[56] Lehnart SE, Mongillo M, Bellinger A, Lindegger N, Chen BX, Hsueh W, et al.
Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden
cardiac death in mice. J Clin Invest 2008;118:2230–45.
[57] Johnson JN, Hofman N, Haglund CM, Cascino GD, Wilde AA, Ackerman MJ.
Identiﬁcation of a possible pathogenic link between congenital long QT
syndrome and epilepsy. Neurology 2009;72:224–31.
[58] MacCormick JM, Crawford JR, Chung SK, Shelling AN, Evans CA, Rees MI, et al.
Symptoms and signs associated with syncope in young people with primary
cardiac arrhythmias. Heart Lung Circ 2011;20:593–8.
[59] Heron SE, Hernandez M, Edwards C, Edkins E, Jansen FE, Scheffer IE, et al.
Neonatal seizures and long QT syndrome: a cardiocerebral channelopathy.
Epilepsia 2010;51:293–6.
[60] Omichi C, Momose Y, Kitahara S. Congenital long QT syndrome presenting with
a history of epilepsy: misdiagnosis or relationship between channelopathies of
the heart and brain. Epilepsia 2010;51:289–92.
[61] Aurlien D, Leren TP, Tauboll E, Gjerstad L. New SCN5A mutation in a SUDEP
victim with idiopathic epilepsy. Seizure 2009;18:158–60.[62] Parisi P, Oliva A, Coll Vidal M, Partemi S, Campuzano O, Iglesias A, et al.
Coexistence of epilepsy and Brugada syndrome in a family with SCN5A
mutation. Epilepsy Res 2013;105:415–8.
[63] Le Gal F, Korff CM, Monso-Hinard C, Mund MT, Morris M, Malafosse A, et al. A
case of SUDEP in a patient with Dravet syndrome with SCN1A mutation.
Epilepsia 2010;51:1915–8.
[64] Hindocha N, Nashef L, Elmslie F, Birch R, Zuberi S, Al-Chalabi A, et al. Two cases
of sudden unexpected death in epilepsy in a GEFS+ family with an SCN1A
mutation. Epilepsia 2008;49:360–5.
[65] Bagnall RD, Crompton DE, Petrovski S, Lam L, Cutmore C, Garry SI, et al.
Exome-based analysis of cardiac arrhythmia, respiratory control and
epilepsy genes in sudden unexpected death in epilepsy. Ann Neurol
2016;79:522–34.
[66] Kenneback G, Bergfeldt L, Vallin H, Tomson T, Edhag O. Electrophysiologic
effects and clinical hazards of carbamazepine treatment for neurologic
disorders in patients with abnormalities of the cardiac conduction system. Am
Heart J 1991;121:1421–9.
[67] Saetre E, Abdelnoor M, Amlie JP, Tossebro M, Perucca E, Tauboll E, et al. Cardiac
function and antiepileptic drug treatment in the elderly: a comparison
between lamotrigine and sustained-release carbamazepine. Epilepsia
2009;50:1841–9.
[68] Sevcencu C, Struijk JJ. Autonomic alterations and cardiac changes in epilepsy.
Epilepsia 2010;51:725–37.
[69] Barron SA. Cardiac arrhythmias after small iv dose of phenytoin. N Engl J Med
1976;295:678.
[70] Kasarskis EJ, Kuo CS, Berger R, Nelson KR. Carbamazepine-induced cardiac
dysfunction: characterization of two distinct clinical syndromes. Arch Intern
Med 1992;152:186–91.
[71] Tomson T, Kenneback G. Arrhythmia, heart rate variability, and antiepileptic
drugs. Epilepsia 1997;38:S48–51.
[72] Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efﬁcacy
and safety of oral lacosamide as adjunctive therapy in adults with partial-
onset seizures. Epilepsia 2007;48:1308–17.
[73] DeSilvey DL, Moss AJ. Primidone in the treatment of the long QT syndrome: QT
shortening and ventricular arrhythmia suppression. Ann Intern Med
1980;93:53–4.
[74] Danielsson BR, Lansdell K, Patmore L, Tomson T. Effects of the antiepileptic
drugs lamotrigine, topiramate and gabapentin on hERG potassium currents.
Epilepsy Res 2005;63:17–25.
[75] Danielsson BR, Lansdell K, Patmore L, Tomson T. Phenytoin and phenobarbital
inhibit human HERG potassium channels. Epilepsy Res 2003;55:147–57.
[76] Hesdorffer DC, Tomson T, Benn E, Sander JW, Nilsson L, Langan Y, et al.
Combined analysis of risk factors for SUDEP. Epilepsia 2011;52:1150–9.
[77] Aurlien D, Larsen JP, Gjerstad L, Tauboll E. Increased risk of sudden unexpected
death in epilepsy in females using lamotrigine: a nested, case-control study.
Epilepsia 2012;53:258–66.
[78] Timmings PL. Sudden unexpected death in epilepsy: a local audit. Seizure
1993;2:287–90.
[79] Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus
precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain
2006;129:1281–92.
[80] Aurlien D, Tauboll E, Gjerstad L. Lamotrigine in idiopathic epilepsy—increased
risk of cardiac death? Acta Neurol Scand 2007;115:199–203.
[81] Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female
gender as a risk factor for torsades de pointes associated with cardiovascular
drugs. JAMA 1993;270:2590–7.
[82] Lehmann MH, Hardy S, Archibald D, MacNeil DJ. JTc prolongation with d,l-
sotalol in women versus men. Am J Cardiol 1999;83:354–9.
[83] Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW,
et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate
for generalised and unclassiﬁable epilepsy: an unblinded randomised
controlled trial. Lancet 2007;369:1016–26.
[84] Mohanraj R, Brodie MJ. Pharmacological outcomes in newly diagnosed
epilepsy. Epilepsy Behav 2005;6:382–7.
[85] Curatolo P, Moavero R, Lo Castro A, Cerminara C. Pharmacotherapy of
idiopathic generalized epilepsies. Expert Opin Pharmacother 2009;10:5–17.
[86] Risgaard B, Waagstein K, Winkel BG, Jabbari R, Lynge TH, Glinge C, et al. Sudden
cardiac death in young adults with previous hospital-based psychiatric
inpatient and outpatient treatment: a nationwide cohort study from Denmark.
J Clin Psychiatry 2015;76:e1122–9.
[87] Emul M, Kalelioglu T. Etiology of cardiovascular disease in patients with
schizophrenia: current perspectives. Neuropsychiatr Dis Treat 2015;11:2493–
503.
[88] Cubeddu LX, Iatrogenic QT. Abnormalities and fatal arrhythmias: mechanisms
and clinical signiﬁcance. Curr Cardiol Rev 2009;5:166–76.
